Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.
From ERS Genomics Sep 5 2024 Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited , the CRISPR licensing Company, and Medicines Discovery Catapult , an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR / Cas9 patent portfolio with MDC’s world-class expertise and technology.
MDC and its partners will benefit from access to ERS’ entire CRISPR/Cas9 portfolio – the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. This will extend MDC’s ability to provide breakthrough products and services that help de-risk drug discovery, drive sector productivity and attract investment.
The agreement adds gene editing to MDC’s already strong research and commercial capabilities in cellular science and biomarkers. MDC and ERS believe the partnership will lead to the development of unique drug discovery tools and unlock insights that will drive faster, more effective drug discovery research in the UK and beyond.
At MDC, we are always looking for the right partnerships to drive innovation across our community, helping them bring medicines to market faster for patient benefit. This agreement with ERS Genomics offers huge potential for entrepreneurial scientists. By using the CRISPR/Cas9 portfolio with our world-class expertise and technologies, we can deliver more breakthroughs together.” John E Milad, CEO, ERS Genomics, said: “We welcome MDC to our family of licensees.
ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including bacteria, archaea, yeasts, and algae. ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.
CRISPR Genomics Drug Discovery Research Technology
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Social genomics: How friends' genes impact a person's mental healthMom always said, 'Choose your friends wisely.' Now a study led by a Rutgers Health professor shows she was onto something: Their traits can rub off on you – especially ones that are in their genes.
Read more »
Wide genetic diversity in South American indigenous groups highlights diversity gap in genomics researchAmazonians are as genetically different from Andeans as Europeans are from East Asians when it comes to genetic variants that affect the response to certain drugs, according to a commentary published August 8 in the journal Cell.
Read more »
Quantum leap in single cell genomics: Scale Bio launches groundbreaking ‘100 million cell challenge’ in collaboration with Ultima Genomics and NVIDIAScale Biosciences (Scale Bio), a leader in innovative and scalable single cell analysis solutions, today announced the launch of the “100 Million Cell Challenge,” a global initiative aimed at pushing the boundaries of single-cell genomics research.
Read more »
Shropshire Farming Talk: Use genomics to unlock herd potentialThe genetic make-up of cattle is more clearly understood than ever before.
Read more »
Three in five Gen Z-ers baffled by quirky names and phrasesA third of Brits admit to not understanding the meaning of commonplace names and phrases - rising to 61% for Gen Z-ers.
Read more »
Gruesome way humans killed 12-ton woolly mammoths in Ice Age finally revealed as scientists squash...Description: Scientists have created a significant breakthrough in the pursuit of de-extinction, particularly of the woolly mammoth. Utilizing CRISPR-Cas9 and pluripotent stem cells, researchers at Colossal Biosciences aim to create an elephant-mammoth hybrid, which could potentially rewild ancient ranges and assist in conservation efforts.
Read more »